Effectiveness and safety of bronchodilators and inhaled corticosteroids in the management of chronic obstructive pulmonary disease


  • Mona Saleh Shalabi Department of Pulmonology, East Jeddah Hospital, Jeddah, Saudi Arabia
  • Sameerah Waheed Aqdi Abu Arish General Hospital, Jazan, Saudi Arabia
  • Odai Ali Alfort Prince Saud bin Jalawi Hospital, Al Ahsa, Saudi Arabia
  • Hassan Abdullah Alqattan Department of Obstetrics and Gynecology, Jubail General Hospital, Jubail, Saudi Arabia
  • Fuad Abdulrahman Alotaibi Medical Services Department, Saudi Red Crescent Authority, Riyadh, Saudi Arabia
  • Afnan Mohammed Faruqui Department of Internal Medicine, Dr. Erfan and Bagedo General Hospital, Jeddah, Saudi Arabia
  • Abrar Saleh Alharbi Department of Pharmacy, Maternity and Children Hospital, Mecca, Saudi Arabia
  • Faisal Fahad Alzahrani Department of Internal Medicine, King Abdulaziz Hospital, Jeddah, Saudi Arabia
  • Sultan Ahmed Yahya College of Medicine, University of Jeddah, Jeddah, Saudi Arabia
  • Alaa Abdulrahman Bakheet Department of Internal Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia
  • Najeeb Mansour Al Mohammedali Eastern Health Cluster, Ministry of Health, Saihat, Saudi Arabia
  • Hamed Saeed Al-Ghamdi Department of Pulmonology, East Jeddah Hospital, Jeddah, Saudi Arabia




COPD, Inhaled, Corticosteroid, Long-acting, Beta-agonist


Chronic obstructive pulmonary disease (COPD) is a lung condition marked by restricted lung airflow. It is a globally prevalent condition affecting almost 300 million individuals. COPD is linked to a significant burden of morbidity and mortality thus necessitating early diagnosis and management. Rising COPD treatment options complicate care and necessitate a review of clinical data to guide treatment choices. Corticosteroids and bronchodilators are the mainstay of treatment for COPD due to their safety and efficacy. Compared to inhaled corticosteroids or long-acting β-agonist therapy alone, inhaled corticosteroids plus long-acting β-agonist lower the risk of exacerbations and enhance lung function and health status in patients with COPD. Patients who experience frequent exacerbations despite taking long-acting bronchodilators and those who have evidence of eosinophilic bronchial inflammation, as shown by high blood eosinophil levels and/or a history of asthma or asthma-COPD overlap, may both benefit greatly from inhaled corticosteroids therapy. Although not widespread, inhaled corticosteroid use is linked to an elevated risk of pneumonia and may vary depending on the particular corticosteroid utilized. Recent research on combination therapy of inhaled corticosteroids and long-acting β-agonist has shown significant advantages and supports its widespread use in COPD patients who experience frequent exacerbations however some clinical studies and trials have also demonstrated quite conflicting outcomes to this therefore necessitating the need for further clinical trials to exhibit conclusive results. The purpose of this research is to review the available information about the effectiveness and safety of bronchodilators and inhaled corticosteroids in the management of COPD.


Olortegui-Rodriguez JJ, Soriano-Moreno DR, Benites-Bullón A, Pelayo-Luis PP, Huaringa-Marcelo J. Prevalence and incidence of chronic obstructive pulmonary disease in Latin America and the Caribbean: a systematic review and meta-analysis. BMC pulmonary medicine. 2022;22(1):273.

Barnes PJ, Burney PG, Silverman EK. Chronic obstructive pulmonary disease. Nature Rev Dis Primers. 2015;1:15076.

Bollmeier SG, Hartmann AP. Management of chronic obstructive pulmonary disease: A review focusing on exacerbations. Am J Heal System Pharmacy. 2020;77(4):259-68.

Disease. GIfCOL. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2019 report. 2019.

Mathioudakis AG, Vestbo J, Singh D. Long-Acting Bronchodilators for Chronic Obstructive Pulmonary Disease: Which One(S), How, and When? Clin Chest Med. 2020;41(3):463-74.

Tashkin DP, Strange C. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? Int J Chron Obstruct Pulmon Dis. 2018;13:2587-601.

Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane database of systematic reviews. 2012;2012(7):Cd002991.

Günay S, Sarıaydın M, Yılmaz Demirci N. New bronchodilators and combinations in COPD treatment. Tuberkuloz Ve Toraks. 2016;64(3):240-5.

Zervas E, Samitas K, Gaga M, Beghe B, Fabbri LM. Inhaled corticosteroids in COPD: pros and cons. Curr Drug Targets. 2013;14(2):192-224.

Agusti A, Fabbri LM, Singh D. Inhaled corticosteroids in COPD: friend or foe? Eur Respiratory J. 2018;52(6).

Kendzerska T, Aaron SD, To T. Effectiveness and Safety of Inhaled Corticosteroids in Older Individuals with Chronic Obstructive Pulmonary Disease and/or Asthma. A Population Study. Ann Am Thoracic Society. 2019;16(10):1252-62.

Amegadzie JE, Gorgui J, Acheampong L, Gamble JM, Farrell J, Gao Z. Comparative safety and effectiveness of inhaled bronchodilators and corticosteroids for treating asthma-COPD overlap: a systematic review and meta-analysis. J Asthma. 2021;58(3):344-59.

Miller-Larsson A, Selroos O. Advances in asthma and COPD treatment: combination therapy with inhaled corticosteroids and long-acting beta 2-agonists. Curr Pharmaceutical Design. 2006;12(25):3261-79.

Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respiratory J. 2015;45(2):525-37.

Zheng J, Baldi S, Zhao L. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial. Respiratory Res. 2021;22(1):90.

Ohar JA, Donohue JF. Mono- and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Seminars Respiratory Crit Care Med. 2010;31(3):321-33.

López-Campos JL, Calero Acuña C. What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease? Expert Rev Respiratory Med. 2013;7(2):43-51.

Nannini LJ, Poole P, Milan SJ, Holmes R, Normansell R. Combined corticosteroid and long-acting beta₂-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Systematic Rev. 2013;2013(11):Cd003794.

Cazzola M, Hanania NA. The role of combination therapy with corticosteroids and long-acting beta2-agonists in the prevention of exacerbations in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(4):345-54.

Monteagudo M, Nuñez A, Barrecheguren M, Miravitlles M. Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study. Archivos De Bronconeumologia. 2022;58(10):699-707.

Di Martino M, Agabiti N, Cascini S. The Effect on Total Mortality of Adding Inhaled Corticosteroids to Long-Acting Bronchodilators for COPD: A Real Practice Analysis in Italy. COPD. 2016;13(3):293-302.

Calverley PM. The role of corticosteroids in chronic obstructive pulmonary disease. Seminars in respiratory and critical care medicine. 2005;26(2):235-45.

Gershon AS, Campitelli MA, Croxford R. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease. JAMA. 2014;312(11):1114-21.




How to Cite

Shalabi, M. S., Aqdi, S. W., Alfort, O. A., Alqattan, H. A., Alotaibi, F. A., Faruqui, A. M., Alharbi, A. S., Alzahrani, F. F., Yahya, S. A., Bakheet, A. A., Al Mohammedali, N. M., & Al-Ghamdi, H. S. (2023). Effectiveness and safety of bronchodilators and inhaled corticosteroids in the management of chronic obstructive pulmonary disease. International Journal Of Community Medicine And Public Health, 10(8), 2955–2959. https://doi.org/10.18203/2394-6040.ijcmph20232392



Review Articles